1-1	0-7	Reduced	_	_
1-2	8-16	Parietal	_	_
1-3	17-22	Alpha	_	_
1-4	23-28	Power	_	_
1-5	29-32	and	_	_
1-6	33-42	Psychotic	_	_
1-7	43-51	Symptoms	_	_
1-8	51-52	:	_	_
1-9	53-64	Test-Retest	_	_
1-10	65-76	Reliability	_	_
1-11	77-79	of	_	_
1-12	80-93	Resting-State	_	_
1-13	94-116	Magnetoencephalography	_	_
1-14	117-119	in	_	_
1-15	120-133	Schizophrenia	_	_
1-16	134-137	and	_	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-17	138-145	Healthy	_	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-18	146-154	Controls	_	_
1-19	155-165	Background	_	_
1-20	165-166	:	_	_
1-21	167-174	Despite	_	_
1-22	175-184	increased	_	_
1-23	185-194	reporting	_	_
1-24	195-197	of	_	_
1-25	198-211	resting-state	_	_
1-26	212-234	magnetoencephalography	_	_
1-27	235-236	(	_	_
1-28	236-239	MEG	_	_
1-29	239-240	)	_	_
1-30	240-241	,	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-31	242-253	reliability	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-32	254-256	of	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-33	257-262	those	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-34	263-271	measures	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-35	272-279	remains	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-36	280-286	scarce	_	_
1-37	287-290	and	_	_
1-38	291-304	predominately	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
1-39	305-313	reported	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
1-40	314-316	in	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-41	317-324	healthy	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-42	325-333	controls	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-43	334-335	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-44	335-337	HC	_	_
1-45	337-338	)	_	_
1-46	338-339	.	_	_

2-1	340-342	As	_	_
2-2	343-347	such	_	_
2-3	347-348	,	_	_
2-4	349-354	there	_	_
2-5	355-357	is	_	_
2-6	358-365	limited	_	_
2-7	366-375	knowledge	_	_
2-8	376-378	on	_	_
2-9	379-382	MEG	_	_
2-10	383-396	resting-state	_	_
2-11	397-408	reliability	_	_
2-12	409-411	in	_	_
2-13	412-425	schizophrenia	_	_
2-14	426-427	(	_	_
2-15	427-429	SZ	_	_
2-16	429-430	)	_	_
2-17	430-431	.	_	_

3-1	432-439	Methods	_	_
3-2	439-440	:	_	_
3-3	441-443	To	_	_
3-4	444-451	address	_	_
3-5	452-463	test-retest	_	_
3-6	464-475	reliability	_	_
3-7	476-478	in	_	_
3-8	479-488	psychosis	_	_
3-9	488-489	,	_	_
3-10	490-491	a	_	_
3-11	492-507	reproducibility	_	_
3-12	508-513	study	_	_
3-13	514-516	of	_	_
3-14	517-519	26	_	_
3-15	520-532	participants	_	_
3-16	533-534	(	_	_
3-17	534-536	13	_	_
3-18	536-537	-	_	_
3-19	537-539	SZ	_	_
3-20	539-540	,	_	_
3-21	541-543	13	_	_
3-22	543-544	-	_	_
3-23	544-546	HC	_	_
3-24	546-547	)	_	_
3-25	548-551	was	_	_
3-26	552-561	performed	_	_
3-27	561-562	.	_	_

4-1	563-565	We	_	_
4-2	566-575	collected	_	_
4-3	576-580	eyes	_	_
4-4	581-585	open	_	_
4-5	586-589	and	_	_
4-6	590-594	eyes	_	_
4-7	595-601	closed	_	_
4-8	602-615	resting-state	_	_
4-9	616-620	data	_	_
4-10	621-627	during	_	_
4-11	628-629	4	_	_
4-12	630-638	separate	_	_
4-13	639-648	instances	_	_
4-14	649-650	(	_	_
4-15	650-651	2	_	_
4-16	652-658	Visits	_	_
4-17	658-659	,	_	_
4-18	660-661	2	_	_
4-19	662-666	runs	_	_
4-20	667-670	per	_	_
4-21	671-676	visit	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
4-22	676-677	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
4-23	678-680	to	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-24	681-689	estimate	_	_
4-25	690-698	spectral	_	_
4-26	699-704	power	_	_
4-27	705-716	reliability	_	_
4-28	717-718	(	_	_
4-29	718-723	power	_	_
4-30	723-724	,	_	_
4-31	725-735	normalized	_	_
4-32	736-741	power	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-33	741-742	,	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-34	743-748	alpha	_	_
4-35	749-759	reactivity	_	_
4-36	759-760	)	_	_
4-37	761-767	across	_	_
4-38	768-771	one	_	_
4-39	772-776	hour	_	_
4-40	777-780	and	_	_
4-41	781-784	one	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-42	785-789	week	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-43	789-790	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging

5-1	791-801	Intraclass	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-2	802-813	correlation	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-3	814-826	coefficients	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-4	827-828	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-5	828-832	ICCs	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-6	832-833	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-7	834-838	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
5-8	839-849	calculated	_	_
5-9	849-850	.	_	_

6-1	851-854	For	_	_
6-2	855-861	source	_	_
6-3	862-870	modeling	_	_
6-4	870-871	,	_	_
6-5	872-874	we	_	_
6-6	875-882	applied	_	_
6-7	883-885	an	_	_
6-8	886-898	anatomically	_	_
6-9	899-910	constrained	_	_
6-10	911-917	linear	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
6-11	918-928	estimation	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
6-12	929-936	inverse	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
6-13	937-942	model	_	_
6-14	943-948	known	_	_
6-15	949-951	as	_	_
6-16	952-959	dynamic	_	_
6-17	960-971	statistical	_	_
6-18	972-982	parametric	_	_
6-19	983-990	mapping	_	_
6-20	991-992	(	_	_
6-21	992-995	MNE	_	_
6-22	996-1000	dSPM	_	_
6-23	1000-1001	)	_	_
6-24	1002-1005	and	_	_
6-25	1006-1018	source-based	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
6-26	1019-1031	connectivity	_	_
6-27	1032-1037	using	_	_
6-28	1038-1041	the	_	_
6-29	1042-1050	weighted	_	_
6-30	1051-1056	phase	_	_
6-31	1057-1060	lag	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
6-32	1061-1066	index	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
6-33	1066-1067	.	_	_

7-1	1068-1075	Results	_	_
7-2	1075-1076	:	_	_
7-3	1077-1083	Across	_	_
7-4	1084-1087	one	_	_
7-5	1088-1092	week	_	_
7-6	1093-1098	there	_	_
7-7	1099-1102	was	_	_
7-8	1103-1112	excellent	_	_
7-9	1113-1124	test-retest	_	_
7-10	1125-1136	reliability	_	_
7-11	1137-1139	in	_	_
7-12	1140-1146	global	_	_
7-13	1147-1155	spectral	_	_
7-14	1156-1164	measures	_	_
7-15	1165-1167	in	_	_
7-16	1168-1179	theta-gamma	_	_
7-17	1180-1185	bands	_	_
7-18	1186-1187	(	_	_
7-19	1187-1189	HC	_	_
7-20	1190-1196	ICCAvg	_	_
7-21	1196-1197	=	_	_
7-22	1197-1201	0.87	_	_
7-23	1201-1202	,	_	_
7-24	1203-1205	SZ	_	_
7-25	1206-1212	ICCAvg	_	_
7-26	1212-1213	=	_	_
7-27	1213-1217	0.87	_	_
7-28	1217-1218	)	_	_
7-29	1218-1219	,	_	_
7-30	1220-1228	regional	_	_
7-31	1229-1237	spectral	_	_
7-32	1238-1246	measures	_	_
7-33	1247-1249	in	_	_
7-34	1250-1253	all	_	_
7-35	1254-1259	bands	_	_
7-36	1260-1261	(	_	_
7-37	1261-1263	HC	_	_
7-38	1264-1270	ICCAvg	_	_
7-39	1270-1271	=	_	_
7-40	1271-1275	0.86	_	_
7-41	1275-1276	,	_	_
7-42	1277-1279	SZ	_	_
7-43	1280-1286	ICCAvg	_	_
7-44	1286-1287	=	_	_
7-45	1287-1291	0.80	_	_
7-46	1291-1292	)	_	_
7-47	1292-1293	,	_	_
7-48	1294-1297	and	_	_
7-49	1298-1306	parietal	_	_
7-50	1307-1312	alpha	_	_
7-51	1313-1321	measures	_	_
7-52	1322-1323	(	_	_
7-53	1323-1325	HC	_	_
7-54	1326-1332	ICCAvg	_	_
7-55	1332-1333	=	_	_
7-56	1333-1337	0.90	_	_
7-57	1337-1338	,	_	_
7-58	1339-1341	SZ	_	_
7-59	1342-1348	ICCAvg	_	_
7-60	1348-1349	=	_	_
7-61	1349-1353	0.84	_	_
7-62	1353-1354	)	_	_
7-63	1354-1355	.	_	_

8-1	1356-1366	Conversely	_	_
8-2	1366-1367	,	_	_
8-3	1368-1378	functional	_	_
8-4	1379-1391	connectivity	_	_
8-5	1392-1395	had	_	_
8-6	1396-1400	poor	_	_
8-7	1401-1412	reliability	_	_
8-8	1412-1413	,	_	_
8-9	1414-1416	as	_	_
8-10	1417-1420	did	_	_
8-11	1421-1427	source	_	_
8-12	1428-1436	spectral	_	_
8-13	1437-1442	power	_	_
8-14	1443-1449	across	_	_
8-15	1450-1453	one	_	_
8-16	1454-1458	hour	_	_
8-17	1459-1462	for	_	_
8-18	1463-1465	SZ	_	_
8-19	1465-1466	.	_	_

9-1	1467-1475	Relative	_	_
9-2	1476-1478	to	_	_
9-3	1479-1481	HC	_	_
9-4	1481-1482	,	_	_
9-5	1483-1485	SZ	_	_
9-6	1486-1490	also	_	_
9-7	1491-1494	had	_	_
9-8	1495-1502	reduced	_	_
9-9	1503-1511	parietal	_	_
9-10	1512-1517	alpha	_	_
9-11	1518-1528	normalized	_	_
9-12	1529-1534	power	_	_
9-13	1535-1541	during	_	_
9-14	1542-1546	eyes	_	_
9-15	1547-1553	closed	_	_
9-16	1554-1558	only	_	_
9-17	1558-1559	,	_	_
9-18	1560-1567	reduced	_	_
9-19	1568-1573	alpha	_	_
9-20	1574-1584	reactivity	_	_
9-21	1584-1585	,	_	_
9-22	1586-1589	and	_	_
9-23	1590-1592	an	_	_
9-24	1593-1604	association	_	_
9-25	1605-1612	between	_	_
9-26	1613-1619	higher	_	_
9-27	1620-1625	PANSS	_	_
9-28	1626-1634	positive	_	_
9-29	1635-1641	scores	_	_
9-30	1642-1645	and	_	_
9-31	1646-1651	lower	_	_
9-32	1652-1660	parietal	_	_
9-33	1661-1666	alpha	_	_
9-34	1667-1672	power	_	_
9-35	1672-1673	.	_	_

10-1	1674-1685	Conclusions	_	_
10-2	1685-1686	:	_	_
10-3	1687-1692	There	_	_
10-4	1693-1696	was	_	_
10-5	1697-1706	excellent	_	_
10-6	1707-1709	to	_	_
10-7	1710-1714	good	_	_
10-8	1715-1726	test-retest	_	_
10-9	1727-1738	reliability	_	_
10-10	1739-1741	in	_	_
10-11	1742-1746	most	_	_
10-12	1747-1750	MEG	_	_
10-13	1751-1759	spectral	_	_
10-14	1760-1768	measures	_	_
10-15	1769-1773	with	_	_
10-16	1774-1775	a	_	_
10-17	1776-1779	few	_	_
10-18	1780-1790	exceptions	_	_
10-19	1791-1793	in	_	_
10-20	1794-1797	the	_	_
10-21	1798-1811	schizophrenia	_	_
10-22	1812-1819	patient	_	_
10-23	1820-1825	group	_	_
10-24	1825-1826	.	_	_

11-1	1827-1834	Overall	_	_
11-2	1834-1835	,	_	_
11-3	1836-1841	these	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-4	1842-1850	findings	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-5	1851-1860	encourage	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-6	1861-1864	the	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-7	1865-1868	use	_	_
11-8	1869-1871	of	_	_
11-9	1872-1885	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
11-10	1886-1889	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
11-11	1890-1895	while	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-12	1896-1907	emphasizing	_	_
11-13	1908-1911	the	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
11-14	1912-1922	importance	_	_
11-15	1923-1925	of	_	_
11-16	1926-1937	determining	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-17	1938-1949	reliability	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-18	1950-1952	in	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-19	1953-1961	clinical	_	_
11-20	1962-1973	populations	_	_
11-21	1973-1974	.	_	_

33-1	6499-6508	Materials	_	_
33-2	6509-6512	and	_	_
33-3	6513-6520	Methods	_	_
33-4	6521-6533	Participants	_	_
33-5	6534-6537	The	_	_
33-6	6538-6545	current	_	_
33-7	6546-6551	study	_	_
33-8	6552-6560	included	_	_
33-9	6561-6563	13	_	_
33-10	6564-6575	individuals	_	_
33-11	6576-6585	diagnosed	_	_
33-12	6586-6590	with	_	_
33-13	6591-6604	schizophrenia	_	_
33-14	6605-6606	(	_	_
33-15	6606-6608	SZ	_	_
33-16	6608-6609	)	_	_
33-17	6610-6613	and	_	_
33-18	6614-6616	13	_	_
33-19	6617-6624	healthy	_	_
33-20	6625-6633	controls	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
33-21	6634-6635	(	_	_
33-22	6635-6637	HC	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-23	6637-6638	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-24	6638-6639	,	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-25	6640-6643	age	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-26	6644-6647	and	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-27	6648-6654	gender	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-28	6655-6662	matched	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-29	6662-6663	,	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-30	6664-6669	Table	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-31	6670-6671	1	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
33-32	6671-6672	.	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_

34-1	6673-6681	Informed	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-2	6682-6689	consent	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-3	6690-6693	was	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-4	6694-6702	obtained	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-5	6703-6707	from	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-6	6708-6711	all	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-7	6712-6724	participants	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-8	6725-6734	according	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-9	6735-6737	to	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
34-10	6738-6751	institutional	_	_
34-11	6752-6762	guidelines	_	_
34-12	6762-6763	.	_	_

35-1	6764-6767	The	_	_
35-2	6768-6773	study	_	_
35-3	6774-6777	was	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
35-4	6778-6786	approved	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
35-5	6787-6789	by	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
35-6	6790-6793	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
35-7	6794-6804	University	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
35-8	6805-6807	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
35-9	6808-6811	New	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
35-10	6812-6818	Mexico	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
35-11	6819-6825	Health	_	_
35-12	6826-6834	Sciences	_	_
35-13	6835-6841	Center	_	_
35-14	6842-6847	Human	_	_
35-15	6848-6856	Research	_	_
35-16	6857-6863	Review	_	_
35-17	6864-6873	Committee	_	_
35-18	6873-6874	.	_	_

36-1	6875-6878	All	_	_
36-2	6879-6891	participants	_	_
36-3	6892-6896	were	_	_
36-4	6897-6903	within	_	_
36-5	6904-6906	21	_	_
36-6	6906-6907	–	_	_
36-7	6907-6909	49	_	_
36-8	6910-6915	years	_	_
36-9	6916-6918	of	_	_
36-10	6919-6922	age	_	_
36-11	6923-6927	with	_	_
36-12	6928-6930	no	_	_
36-13	6931-6938	history	_	_
36-14	6939-6941	of	_	_
36-15	6942-6954	neurological	_	_
36-16	6955-6963	disorder	_	_
36-17	6964-6965	(	_	_
36-18	6965-6968	e.g	_	_
36-19	6968-6969	.	_	_
36-20	6970-6978	epilepsy	_	_
36-21	6978-6979	)	_	_
36-22	6979-6980	,	_	_
36-23	6981-6983	no	_	_
36-24	6984-6991	history	_	_
36-25	6992-6994	of	_	_
36-26	6995-7000	major	_	_
36-27	7001-7005	head	_	_
36-28	7006-7012	trauma	_	_
36-29	7013-7014	(	_	_
36-30	7014-7018	loss	_	_
36-31	7019-7021	of	_	_
36-32	7022-7035	consciousness	_	_
36-33	7036-7037	>	_	_
36-34	7037-7038	5	_	_
36-35	7039-7042	min	_	_
36-36	7042-7043	)	_	_
36-37	7043-7044	,	_	_
36-38	7045-7047	no	_	_
36-39	7048-7055	current	_	_
36-40	7056-7065	substance	_	_
36-41	7066-7071	abuse	_	_
36-42	7072-7081	diagnosis	_	_
36-43	7082-7083	(	_	_
36-44	7083-7092	excluding	_	_
36-45	7093-7101	nicotine	_	_
36-46	7101-7102	)	_	_
36-47	7102-7103	,	_	_
36-48	7104-7106	no	_	_
36-49	7107-7114	current	_	_
36-50	7115-7125	dependence	_	_
36-51	7125-7126	/	_	_
36-52	7126-7131	abuse	_	_
36-53	7132-7134	of	_	_
36-54	7135-7138	PCP	_	_
36-55	7138-7139	/	_	_
36-56	7139-7150	amphetamine	_	_
36-57	7150-7151	/	_	_
36-58	7151-7158	cocaine	_	_
36-59	7159-7165	within	_	_
36-60	7166-7169	the	_	_
36-61	7170-7174	past	_	_
36-62	7175-7177	12	_	_
36-63	7178-7184	months	_	_
36-64	7184-7185	,	_	_
36-65	7186-7189	and	_	_
36-66	7190-7194	were	_	_
36-67	7195-7198	not	_	_
36-68	7199-7208	currently	_	_
36-69	7209-7211	on	_	_
36-70	7212-7216	mood	_	_
36-71	7217-7228	stabilizers	_	_
36-72	7229-7233	such	_	_
36-73	7234-7236	as	_	_
36-74	7237-7244	lithium	_	_
36-75	7245-7247	or	_	_
36-76	7248-7256	valproic	_	_
36-77	7257-7261	acid	_	_
36-78	7261-7262	.	_	_

37-1	7263-7265	HC	_	_
37-2	7266-7269	had	_	_
37-3	7270-7272	IQ	_	_
37-4	7273-7279	scores	_	_
37-5	7280-7286	within	_	_
37-6	7287-7290	the	_	_
37-7	7291-7297	normal	_	_
37-8	7298-7303	range	_	_
37-9	7304-7307	and	_	_
37-10	7308-7310	no	_	_
37-11	7311-7318	history	_	_
37-12	7319-7321	of	_	_
37-13	7322-7335	developmental	_	_
37-14	7336-7342	delays	_	_
37-15	7343-7345	or	_	_
37-16	7346-7358	neurological	_	_
37-17	7359-7361	or	_	_
37-18	7362-7373	psychiatric	_	_
37-19	7374-7383	disorders	_	_
37-20	7384-7389	based	_	_
37-21	7390-7392	on	_	_
37-22	7393-7396	the	_	_
37-23	7397-7407	Structured	_	_
37-24	7408-7416	Clinical	_	_
37-25	7417-7426	Interview	_	_
37-26	7427-7430	for	_	_
37-27	7431-7449	DSM-IV-Non-patient	_	_
37-28	7450-7451	(	_	_
37-29	7451-7457	SCIDNP	_	_
37-30	7457-7458	)	_	_
37-31	7458-7459	.	_	_

38-1	7460-7463	HCs	_	_
38-2	7464-7468	also	_	_
38-3	7469-7472	did	_	_
38-4	7473-7476	not	_	_
38-5	7477-7481	have	_	_
38-6	7482-7483	a	_	_
38-7	7484-7490	family	_	_
38-8	7491-7498	history	_	_
38-9	7499-7501	of	_	_
38-10	7502-7503	a	_	_
38-11	7504-7513	psychotic	_	_
38-12	7514-7522	disorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
38-13	7523-7525	in	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
38-14	7526-7538	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
38-15	7539-7548	relatives	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
38-16	7549-7551	or	_	_
38-17	7552-7553	a	_	_
38-18	7554-7561	history	_	_
38-19	7562-7564	of	_	_
38-20	7565-7569	more	_	_
38-21	7570-7574	than	_	_
38-22	7575-7576	1	_	_
38-23	7577-7585	lifetime	_	_
38-24	7586-7596	depressive	_	_
38-25	7597-7604	episode	_	_
38-26	7604-7605	.	_	_

39-1	7606-7618	Participants	_	_
39-2	7619-7623	with	_	_
39-3	7624-7637	schizophrenia	_	_
39-4	7638-7642	were	_	_
39-5	7643-7652	confirmed	_	_
39-6	7653-7655	to	_	_
39-7	7656-7660	have	_	_
39-8	7661-7662	a	_	_
39-9	7663-7672	DSM-IV-TR	_	_
39-10	7673-7682	diagnosis	_	_
39-11	7683-7685	of	_	_
39-12	7686-7699	schizophrenia	_	_
39-13	7700-7704	with	_	_
39-14	7705-7708	the	_	_
39-15	7709-7719	Structured	_	_
39-16	7720-7728	Clinical	_	_
39-17	7729-7738	Interview	_	_
39-18	7739-7742	for	_	_
39-19	7743-7757	DSM-IV-Patient	_	_
39-20	7758-7759	(	_	_
39-21	7759-7766	SCID-IP	_	_
39-22	7766-7767	)	_	_
39-23	7768-7771	and	_	_
39-24	7772-7785	retrospective	_	_
39-25	7786-7794	clinical	_	_
39-26	7795-7804	stability	_	_
39-27	7804-7805	.	_	_

40-1	7806-7818	Participants	_	_
40-2	7819-7823	were	_	_
40-3	7824-7827	not	_	_
40-4	7828-7836	excluded	_	_
40-5	7837-7840	for	_	_
40-6	7841-7849	nicotine	_	_
40-7	7850-7853	use	_	_
40-8	7853-7854	,	_	_
40-9	7855-7862	however	_	_
40-10	7862-7863	,	_	_
40-11	7864-7868	they	_	_
40-12	7869-7873	were	_	_
40-13	7874-7877	not	_	_
40-14	7878-7885	allowed	_	_
40-15	7886-7888	to	_	_
40-16	7889-7894	smoke	_	_
40-17	7895-7901	within	_	_
40-18	7902-7903	1	_	_
40-19	7904-7908	hour	_	_
40-20	7909-7911	of	_	_
40-21	7912-7915	the	_	_
40-22	7916-7919	MEG	_	_
40-23	7920-7927	session	_	_
40-24	7928-7930	or	_	_
40-25	7931-7933	be	_	_
40-26	7934-7938	more	_	_
40-27	7939-7943	than	_	_
40-28	7944-7945	5	_	_
40-29	7946-7951	hours	_	_
40-30	7952-7956	from	_	_
40-31	7957-7962	their	_	_
40-32	7963-7971	previous	_	_
40-33	7972-7981	cigarette	_	_
40-34	7982-7984	to	_	_
40-35	7985-7990	avoid	_	_
40-36	7991-8000	confounds	_	_
40-37	8001-8003	of	_	_
40-38	8004-8009	acute	_	_
40-39	8010-8018	nicotine	_	_
40-40	8019-8027	exposure	_	_
40-41	8028-8030	or	_	_
40-42	8031-8041	withdrawal	_	_
40-43	8041-8042	.	_	_

41-1	8043-8046	The	_	_
41-2	8047-8056	following	_	_
41-3	8057-8068	assessments	_	_
41-4	8069-8073	were	_	_
41-5	8074-8083	collected	_	_
41-6	8084-8086	in	_	_
41-7	8087-8089	SZ	_	_
41-8	8090-8102	participants	_	_
41-9	8103-8106	and	_	_
41-10	8107-8115	reported	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	_
41-11	8116-8118	in	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	_
41-12	8119-8124	Table	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#SleepAndHealthModifiedScoreQuestionnaire
41-13	8125-8126	1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	_
41-14	8126-8127	:	_	_
41-15	8128-8136	Wechsler	_	_
41-16	8137-8141	Test	_	_
41-17	8142-8144	of	_	_
41-18	8145-8150	Adult	_	_
41-19	8151-8158	Reading	_	_
41-20	8159-8160	(	_	_
41-21	8160-8164	WTAR	_	_
41-22	8164-8165	)	_	_
41-23	8165-8166	,	_	_
41-24	8167-8175	Standard	_	_
41-25	8176-8179	and	_	_
41-26	8180-8189	Predicted	_	_
41-27	8190-8191	(	_	_
41-28	8191-8200	premorbid	_	_
41-29	8200-8201	)	_	_
41-30	8202-8204	IQ	_	_
41-31	8204-8205	,	_	_
41-32	8206-8214	Positive	_	_
41-33	8215-8218	and	_	_
41-34	8219-8227	Negative	_	_
41-35	8228-8236	Syndrome	_	_
41-36	8237-8242	Scale	_	_
41-37	8243-8244	(	_	_
41-38	8244-8249	PANSS	_	_
41-39	8249-8250	)	_	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingSession
41-40	8250-8251	,	_	_
41-41	8252-8265	antipsychotic	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
41-42	8266-8276	medication	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
41-43	8277-8281	dose	_	_
41-44	8282-8293	information	_	_
41-45	8293-8294	,	_	_
41-46	8295-8298	and	_	_
41-47	8299-8307	duration	_	_
41-48	8308-8310	of	_	_
41-49	8311-8318	illness	_	_
41-50	8318-8319	.	_	_

42-1	8320-8325	PANSS	_	_
42-2	8326-8332	scores	_	_
42-3	8333-8337	were	_	_
42-4	8338-8348	determined	_	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingSession
42-5	8349-8352	for	_	_
42-6	8353-8357	each	_	_
42-7	8358-8363	visit	_	_
42-8	8363-8364	.	_	_

43-1	8365-8378	Antipsychotic	_	_
43-2	8379-8389	medication	_	_
43-3	8390-8393	was	_	_
43-4	8394-8403	converted	_	_
43-5	8404-8406	to	_	_
43-6	8407-8417	olanzapine	_	_
43-7	8418-8429	equivalents	_	_
43-8	8430-8433	for	_	_
43-9	8434-8444	comparison	_	_
43-10	8445-8452	between	_	_
43-11	8453-8463	medication	_	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
43-12	8463-8464	.	_	http://maven.renci.org/NeuroBridge/neurobridge#Intervention

44-1	8465-8473	Duration	_	_
44-2	8474-8476	of	_	_
44-3	8477-8484	illness	_	_
44-4	8485-8488	was	_	_
44-5	8489-8499	calculated	_	_
44-6	8500-8502	by	_	_
44-7	8503-8514	subtracting	_	_
44-8	8515-8518	age	_	_
44-9	8519-8521	at	_	_
44-10	8522-8527	onset	_	_
44-11	8528-8530	of	_	_
44-12	8531-8540	psychotic	_	_
44-13	8541-8549	symptoms	_	_
44-14	8550-8554	from	_	_
44-15	8555-8562	current	_	_
44-16	8563-8566	age	_	_
44-17	8566-8567	.	_	_

45-1	8568-8571	MEG	_	_
45-2	8572-8582	Behavioral	_	_
45-3	8583-8588	Tasks	_	_
45-4	8589-8592	All	_	_
45-5	8593-8605	participants	_	_
45-6	8606-8609	had	_	_
45-7	8610-8613	two	_	_
45-8	8614-8620	visits	_	_
45-9	8621-8627	across	_	_
45-10	8628-8629	7	_	_
45-11	8630-8634	days	_	_
45-12	8635-8636	[	_	_
45-13	8636-8638	HC	_	_
45-14	8638-8639	=	_	_
45-15	8639-8643	7.54	_	_
45-16	8644-8648	days	_	_
45-17	8649-8650	±	_	_
45-18	8650-8652	60	_	_
45-19	8653-8660	minutes	_	_
45-20	8660-8661	,	_	_
45-21	8662-8664	SZ	_	_
45-22	8664-8665	=	_	_
45-23	8665-8669	7.84	_	_
45-24	8670-8674	days	_	_
45-25	8675-8676	±	_	_
45-26	8676-8678	51	_	_
45-27	8679-8686	minutes	_	_
45-28	8686-8687	]	_	_
45-29	8687-8688	.	_	_

46-1	8689-8693	Time	_	_
46-2	8694-8696	of	_	_
46-3	8697-8700	day	_	_
46-4	8701-8708	between	_	_
46-5	8709-8715	visits	_	_
46-6	8716-8719	was	_	_
46-7	8720-8727	matched	_	_
46-8	8728-8730	to	_	_
46-9	8731-8735	take	_	_
46-10	8736-8740	into	_	_
46-11	8741-8748	account	_	_
46-12	8749-8758	circadian	_	_
46-13	8759-8765	rhythm	_	_
46-14	8765-8766	.	_	_

47-1	8767-8771	Each	_	_
47-2	8772-8777	visit	_	_
47-3	8778-8783	began	_	_
47-4	8784-8788	with	_	_
47-5	8789-8790	a	_	_
47-6	8791-8793	10	_	_
47-7	8793-8794	-	_	_
47-8	8794-8800	minute	_	_
47-9	8801-8805	rest	_	_
47-10	8806-8810	task	_	_
47-11	8811-8812	(	_	_
47-12	8812-8820	referred	_	_
47-13	8821-8823	to	_	_
47-14	8824-8826	as	_	_
47-15	8827-8833	Rest10	_	_
47-16	8833-8834	)	_	_
47-17	8835-8838	and	_	_
47-18	8839-8844	ended	_	_
47-19	8845-8849	with	_	_
47-20	8850-8851	a	_	_
47-21	8852-8853	4	_	_
47-22	8853-8854	-	_	_
47-23	8854-8860	minute	_	_
47-24	8861-8865	rest	_	_
47-25	8866-8870	task	_	_
47-26	8871-8872	(	_	_
47-27	8872-8880	referred	_	_
47-28	8881-8883	to	_	_
47-29	8884-8886	as	_	_
47-30	8887-8892	Rest4	_	_
47-31	8892-8893	)	_	_
47-32	8893-8894	,	_	_
47-33	8895-8898	see	_	_
47-34	8899-8905	Figure	_	_
47-35	8906-8907	1	_	_
47-36	8907-8908	.	_	_

48-1	8909-8911	No	_	_
48-2	8912-8921	responses	_	_
48-3	8922-8926	were	_	_
48-4	8927-8935	required	_	_
48-5	8936-8940	from	_	_
48-6	8941-8944	the	_	_
48-7	8945-8956	participant	_	_
48-8	8956-8957	;	_	_
48-9	8958-8965	however	_	_
48-10	8965-8966	,	_	_
48-11	8967-8979	participants	_	_
48-12	8980-8984	were	_	_
48-13	8985-8995	instructed	_	_
48-14	8996-8998	to	_	_
48-15	8999-9005	attend	_	_
48-16	9006-9009	the	_	_
48-17	9010-9022	instructions	_	_
48-18	9023-9026	for	_	_
48-19	9027-9034	prompts	_	_
48-20	9035-9037	to	_	_
48-21	9038-9043	close	_	_
48-22	9044-9049	their	_	_
48-23	9050-9054	eyes	_	_
48-24	9055-9057	or	_	_
48-25	9058-9064	fixate	_	_
48-26	9065-9067	on	_	_
48-27	9068-9069	a	_	_
48-28	9070-9075	white	_	_
48-29	9076-9081	cross	_	_
48-30	9081-9082	.	_	_

49-1	9083-9087	Each	_	_
49-2	9088-9092	task	_	_
49-3	9093-9103	alternated	_	_
49-4	9104-9111	between	_	_
49-5	9112-9114	EC	_	_
49-6	9115-9118	and	_	_
49-7	9119-9121	EO	_	_
49-8	9121-9122	.	_	_

50-1	9123-9125	In	_	_
50-2	9126-9131	total	_	_
50-3	9131-9132	,	_	_
50-4	9133-9146	resting-state	_	_
50-5	9147-9155	activity	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
50-6	9156-9159	was	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
50-7	9160-9168	recorded	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
50-8	9169-9170	4	_	_
50-9	9171-9179	separate	_	_
50-10	9180-9185	times	_	_
50-11	9186-9190	with	_	_
50-12	9191-9193	14	_	_
50-13	9194-9201	minutes	_	_
50-14	9202-9204	of	_	_
50-15	9205-9207	EO	_	_
50-16	9208-9211	and	_	_
50-17	9212-9214	14	_	_
50-18	9215-9222	minutes	_	_
50-19	9223-9225	of	_	_
50-20	9226-9228	EC	_	_
50-21	9228-9229	.	_	_

51-1	9230-9233	MEG	_	_
51-2	9234-9238	Data	_	_
51-3	9239-9250	Acquisition	_	_
51-4	9251-9254	MEG	_	_
51-5	9255-9259	data	_	_
51-6	9260-9264	were	_	_
51-7	9265-9274	collected	_	_
51-8	9275-9277	in	_	_
51-9	9278-9279	a	_	_
51-10	9280-9292	magnetically	_	_
51-11	9293-9301	shielded	_	_
51-12	9302-9306	room	_	_
51-13	9307-9308	(	_	_
51-14	9308-9322	Vacuumschmelze	_	_
51-15	9323-9324	–	_	_
51-16	9325-9329	Ak3B	_	_
51-17	9329-9330	)	_	_
51-18	9331-9333	at	_	_
51-19	9334-9337	the	_	_
51-20	9338-9342	Mind	_	_
51-21	9343-9351	Research	_	_
51-22	9352-9359	Network	_	_
51-23	9360-9362	in	_	_
51-24	9363-9374	Albuquerque	_	_
51-25	9374-9375	,	_	_
51-26	9376-9379	New	_	_
51-27	9380-9386	Mexico	_	_
51-28	9387-9392	using	_	_
51-29	9393-9394	a	_	_
51-30	9395-9398	306	_	_
51-31	9398-9399	-	_	_
51-32	9399-9406	channel	_	_
51-33	9407-9417	whole-head	_	_
51-34	9418-9421	MEG	_	_
51-35	9422-9428	system	_	_
51-36	9429-9430	(	_	_
51-37	9430-9436	Elekta	_	_
51-38	9437-9445	Neuromag	_	_
51-39	9445-9446	)	_	_
51-40	9447-9451	with	_	_
51-41	9452-9453	a	_	_
51-42	9454-9462	sampling	_	_
51-43	9463-9467	rate	_	_
51-44	9468-9470	of	_	_
51-45	9471-9475	1000	_	_
51-46	9476-9478	Hz	_	_
51-47	9479-9482	and	_	_
51-48	9483-9485	an	_	_
51-49	9486-9498	antialiasing	_	_
51-50	9499-9505	filter	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale	_
51-51	9506-9510	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale	_
51-52	9511-9512	a	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale	_
51-53	9513-9521	passband	_	_
51-54	9522-9524	of	_	_
51-55	9525-9528	0.1	_	_
51-56	9528-9529	–	_	_
51-57	9529-9532	330	_	_
51-58	9533-9535	Hz	_	_
51-59	9535-9536	.	_	_

52-1	9537-9542	Prior	_	_
52-2	9543-9545	to	_	_
52-3	9546-9550	data	_	_
52-4	9551-9562	acquisition	_	_
52-5	9562-9563	,	_	_
52-6	9564-9568	four	_	_
52-7	9569-9584	electromagnetic	_	_
52-8	9585-9590	coils	_	_
52-9	9591-9595	were	_	_
52-10	9596-9602	placed	_	_
52-11	9603-9605	on	_	_
52-12	9606-9609	the	_	_
52-13	9610-9621	participant	_	_
52-14	9621-9622	’	_	_
52-15	9622-9623	s	_	_
52-16	9624-9631	mastoid	_	_
52-17	9632-9636	bone	_	_
52-18	9637-9640	and	_	_
52-19	9641-9646	upper	_	_
52-20	9647-9655	forehead	_	_
52-21	9655-9656	,	_	_
52-22	9657-9662	along	_	_
52-23	9663-9667	with	_	_
52-24	9668-9685	electro-oculogram	_	_
52-25	9686-9689	and	_	_
52-26	9690-9707	electrocardiogram	_	_
52-27	9708-9716	channels	_	_
52-28	9716-9717	.	_	_

53-1	9718-9721	The	_	_
53-2	9722-9730	location	_	_
53-3	9731-9733	of	_	_
53-4	9734-9737	the	_	_
53-5	9738-9743	coils	_	_
53-6	9744-9748	were	_	_
53-7	9749-9759	registered	_	_
53-8	9760-9762	to	_	_
53-9	9763-9766	the	_	_
53-10	9767-9773	nasion	_	_
53-11	9774-9777	and	_	_
53-12	9778-9790	preauricular	_	_
53-13	9791-9797	points	_	_
53-14	9798-9803	using	_	_
53-15	9804-9821	three-dimensional	_	_
53-16	9822-9834	digitization	_	_
53-17	9835-9844	equipment	_	_
53-18	9845-9846	(	_	_
53-19	9846-9854	Polhemus	_	_
53-20	9855-9864	FastTrack	_	_
53-21	9864-9865	)	_	_
53-22	9865-9866	.	_	_

54-1	9867-9879	Participants	_	_
54-2	9880-9883	sat	_	_
54-3	9884-9891	upright	_	_
54-4	9892-9894	in	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
54-5	9895-9898	the	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
54-6	9899-9902	MEG	_	_
54-7	9903-9909	during	_	_
54-8	9910-9913	the	_	_
54-9	9914-9918	task	_	_
54-10	9918-9919	.	_	_

55-1	9920-9930	Continuous	_	_
55-2	9931-9935	Head	_	_
55-3	9936-9944	Position	_	_
55-4	9945-9954	Indicator	_	_
55-5	9955-9956	(	_	_
55-6	9956-9960	cHPI	_	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
55-7	9960-9961	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
55-8	9962-9972	monitoring	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
55-9	9973-9980	allowed	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
55-10	9981-9984	for	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
55-11	9985-9991	motion	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
55-12	9992-10002	correction	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
55-13	10002-10003	.	_	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion

56-1	10004-10008	Head	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
56-2	10009-10017	position	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
56-3	10018-10021	was	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
56-4	10022-10029	checked	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
56-5	10030-10037	between	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
56-6	10038-10044	visits	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
56-7	10044-10045	.	_	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale

57-1	10046-10049	For	_	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
57-2	10050-10053	the	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-3	10054-10060	Rest10	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-4	10061-10065	task	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-5	10065-10066	,	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-6	10067-10074	average	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-7	10075-10084	Euclidean	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-8	10085-10093	distance	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-9	10094-10101	between	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
57-10	10102-10108	visits	_	_
57-11	10109-10112	was	_	_
57-12	10113-10117	4.62	_	_
57-13	10118-10120	mm	_	_
57-14	10121-10124	for	_	_
57-15	10125-10127	HC	_	_
57-16	10128-10131	and	_	_
57-17	10132-10136	6.06	_	_
57-18	10137-10139	mm	_	_
57-19	10140-10143	for	_	_
57-20	10144-10146	SZ	_	_
57-21	10146-10147	.	_	_

58-1	10148-10151	For	_	_
58-2	10152-10155	the	_	_
58-3	10156-10161	Rest4	_	_
58-4	10162-10166	task	_	_
58-5	10166-10167	,	_	_
58-6	10168-10171	the	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
58-7	10172-10180	distance	_	_
58-8	10181-10184	was	_	_
58-9	10185-10189	4.90	_	_
58-10	10190-10192	mm	_	_
58-11	10193-10196	for	_	_
58-12	10197-10199	HC	_	_
58-13	10200-10203	and	_	_
58-14	10204-10208	6.12	_	_
58-15	10209-10211	mm	_	_
58-16	10212-10215	for	_	_
58-17	10216-10218	SZ	_	_
58-18	10218-10219	.	_	_

59-1	10220-10224	Head	_	_
59-2	10225-10233	position	_	_
59-3	10234-10245	consistency	_	_
59-4	10246-10249	was	_	_
59-5	10250-10257	similar	_	_
59-6	10258-10265	between	_	_
59-7	10266-10268	HC	_	_
59-8	10269-10272	and	_	_
59-9	10273-10275	SZ	_	_
59-10	10276-10277	(	_	_
59-11	10277-10280	all	_	_
59-12	10281-10282	p	_	_
59-13	10282-10283	’	_	_
59-14	10283-10284	s	_	_
59-15	10284-10285	>	_	_
59-16	10285-10289	0.31	_	_
59-17	10289-10290	)	_	_
59-18	10290-10291	.	_	_

60-1	10292-10302	Structural	_	_
60-2	10303-10306	MRI	_	_
60-3	10307-10311	Data	_	_
60-4	10312-10323	Acquisition	_	_
60-5	10324-10334	Structural	_	_
60-6	10335-10339	MRIs	_	_
60-7	10340-10344	were	_	_
60-8	10345-10353	obtained	_	_
60-9	10354-10357	for	_	_
60-10	10358-10365	mapping	_	_
60-11	10366-10372	source	_	_
60-12	10373-10382	locations	_	_
60-13	10382-10383	.	_	_

61-1	10384-10392	Sagittal	_	_
61-2	10393-10395	T1	_	_
61-3	10395-10396	-	_	_
61-4	10396-10404	weighted	_	_
61-5	10405-10415	anatomical	_	_
61-6	10416-10418	MR	_	_
61-7	10419-10425	images	_	_
61-8	10426-10430	were	_	_
61-9	10431-10439	obtained	_	_
61-10	10440-10445	using	_	_
61-11	10446-10447	a	_	_
61-12	10448-10455	Siemens	_	_
61-13	10456-10459	TIM	_	_
61-14	10460-10464	Trio	_	_
61-15	10465-10466	3	_	_
61-16	10467-10472	Tesla	_	_
61-17	10473-10476	MRI	_	_
61-18	10477-10483	system	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_
61-19	10484-10488	with	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
61-20	10489-10490	a	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
61-21	10491-10493	32	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
61-22	10493-10494	-	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
61-23	10494-10501	channel	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
61-24	10502-10506	head	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
61-25	10507-10511	coil	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
61-26	10511-10512	.	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_

62-1	10513-10523	Parameters	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_
62-2	10524-10526	of	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#BerlinQuestionnaire
62-3	10527-10530	the	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_
62-4	10531-10540	multiecho	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#orderedPointingTest
62-5	10541-10543	3D	_	_
62-6	10544-10550	MPRAGE	_	_
62-7	10551-10559	sequence	_	_
62-8	10560-10564	were	_	_
62-9	10564-10565	:	_	_
62-10	10566-10568	TR	_	_
62-11	10568-10569	/	_	_
62-12	10569-10571	TE	_	_
62-13	10571-10572	/	_	_
62-14	10572-10574	TI	_	_
62-15	10575-10576	=	_	_
62-16	10577-10581	2530	_	_
62-17	10581-10582	/	_	_
62-18	10582-10586	1.64	_	_
62-19	10586-10587	,	_	_
62-20	10588-10591	3.5	_	_
62-21	10591-10592	,	_	_
62-22	10593-10597	5.36	_	_
62-23	10597-10598	,	_	_
62-24	10599-10603	7.22	_	_
62-25	10603-10604	,	_	_
62-26	10605-10609	9.08	_	_
62-27	10609-10610	/	_	_
62-28	10610-10614	1200	_	_
62-29	10615-10617	ms	_	_
62-30	10617-10618	,	_	_
62-31	10619-10623	flip	_	_
62-32	10624-10629	angle	_	_
62-33	10630-10631	=	_	_
62-34	10632-10633	7	_	_
62-35	10633-10634	°	_	_
62-36	10634-10635	,	_	_
62-37	10636-10641	field	_	_
62-38	10642-10644	of	_	_
62-39	10645-10649	view	_	_
62-40	10650-10651	(	_	_
62-41	10651-10654	FOV	_	_
62-42	10654-10655	)	_	_
62-43	10656-10657	=	_	_
62-44	10658-10661	256	_	_
62-45	10662-10664	mm	_	_
62-46	10665-10666	x	_	_
62-47	10667-10670	256	_	_
62-48	10671-10673	mm	_	_
62-49	10673-10674	,	_	_
62-50	10675-10681	matrix	_	_
62-51	10682-10683	=	_	_
62-52	10684-10687	256	_	_
62-53	10688-10689	×	_	_
62-54	10690-10693	256	_	_
62-55	10693-10694	,	_	_
62-56	10695-10696	1	_	_
62-57	10697-10699	mm	_	_
62-58	10700-10705	thick	_	_
62-59	10706-10711	slice	_	_
62-60	10711-10712	,	_	_
62-61	10713-10716	192	_	_
62-62	10717-10723	slices	_	_
62-63	10723-10724	,	_	_
62-64	10725-10731	GRAPPA	_	_
62-65	10732-10744	acceleration	_	_
62-66	10745-10746	=	_	_
62-67	10747-10748	2	_	_
62-68	10748-10749	.	_	_

63-1	10750-10753	MEG	_	_
63-2	10754-10758	Data	_	_
63-3	10759-10772	Preprocessing	_	_
63-4	10773-10776	Raw	_	_
63-5	10777-10780	MEG	_	_
63-6	10781-10785	data	_	_
63-7	10786-10790	were	_	_
63-8	10791-10799	filtered	_	_
63-9	10800-10803	for	_	_
63-10	10804-10809	noise	_	_
63-11	10810-10813	and	_	_
63-12	10814-10823	corrected	_	_
63-13	10824-10827	for	_	_
63-14	10828-10832	head	_	_
63-15	10833-10839	motion	_	_
63-16	10840-10844	with	_	_
63-17	10845-10848	the	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
63-18	10849-10857	Neuromag	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
63-19	10858-10868	Max-Filter	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
63-20	10869-10872	2.2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
63-21	10873-10881	software	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
63-22	10882-10887	using	_	_
63-23	10888-10891	the	_	_
63-24	10892-10900	temporal	_	_
63-25	10901-10910	extension	_	_
63-26	10911-10913	of	_	_
63-27	10914-10920	signal	_	_
63-28	10921-10926	space	_	_
63-29	10927-10937	separation	_	_
63-30	10938-10939	(	_	_
63-31	10939-10944	t-SSS	_	_
63-32	10944-10945	)	_	_
63-33	10946-10952	method	_	_
63-34	10953-10957	with	_	_
63-35	10958-10966	movement	_	_
63-36	10967-10979	compensation	_	_
63-37	10979-10980	.	_	_

64-1	10981-10984	MEG	_	_
64-2	10985-10989	data	_	_
64-3	10990-10994	from	_	_
64-4	10995-10999	each	_	_
64-5	11000-11007	subject	_	_
64-6	11007-11008	’	_	_
64-7	11008-11009	s	_	_
64-8	11010-11015	Visit	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
64-9	11016-11017	2	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
64-10	11018-11021	was	_	_
64-11	11022-11033	transformed	_	_
64-12	11034-11036	to	_	_
64-13	11037-11042	Visit	_	_
64-14	11043-11044	1	_	_
64-15	11045-11049	head	_	_
64-16	11050-11058	position	_	_
64-17	11059-11064	using	_	_
64-18	11065-11074	Maxfilter	_	_
64-19	11075-11078	2.2	_	_
64-20	11079-11086	MaxMove	_	_
64-21	11087-11093	option	_	_
64-22	11094-11096	to	_	_
64-23	11097-11103	ensure	_	_
64-24	11104-11114	equivalent	_	_
64-25	11115-11121	sensor	_	_
64-26	11122-11131	locations	_	_
64-27	11132-11139	between	_	_
64-28	11140-11146	visits	_	_
64-29	11146-11147	.	_	_

65-1	11148-11150	No	_	_
65-2	11151-11163	downsampling	_	_
65-3	11164-11166	of	_	_
65-4	11167-11170	the	_	_
65-5	11171-11175	data	_	_
65-6	11176-11179	was	_	_
65-7	11180-11191	implemented	_	_
65-8	11192-11194	at	_	_
65-9	11195-11198	the	_	_
65-10	11199-11212	preprocessing	_	_
65-11	11213-11218	stage	_	_
65-12	11218-11219	.	_	_

66-1	11220-11229	Heartbeat	_	_
66-2	11230-11233	and	_	_
66-3	11234-11243	eye-blink	_	_
66-4	11244-11253	artifacts	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
66-5	11254-11258	were	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
66-6	11259-11272	automatically	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
66-7	11273-11281	detected	_	_
66-8	11282-11285	and	_	_
66-9	11286-11293	removed	_	_
66-10	11294-11299	using	_	_
66-11	11300-11306	signal	_	_
66-12	11307-11312	space	_	_
66-13	11313-11323	projection	_	_
66-14	11324-11325	(	_	_
66-15	11325-11328	SSP	_	_
66-16	11328-11329	)	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	_
66-17	11330-11332	in	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
66-18	11333-11336	MNE	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
66-19	11337-11345	software	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
66-20	11345-11346	.	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging

67-1	11347-11350	The	_	_
67-2	11351-11361	continuous	_	_
67-3	11362-11366	data	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
67-4	11367-11371	were	_	_
67-5	11372-11381	segmented	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
67-6	11382-11386	into	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
67-7	11387-11400	artifact-free	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
67-8	11401-11402	2	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
67-9	11403-11409	second	_	_
67-10	11410-11416	epochs	_	_
67-11	11416-11417	.	_	_

68-1	11418-11424	Epochs	_	_
68-2	11425-11427	in	_	_
68-3	11428-11433	which	_	_
68-4	11434-11437	the	_	_
68-5	11438-11446	magnetic	_	_
68-6	11447-11452	field	_	_
68-7	11453-11461	exceeded	_	_
68-8	11462-11463	5	_	_
68-9	11464-11466	pT	_	_
68-10	11467-11471	were	_	_
68-11	11472-11480	rejected	_	_
68-12	11480-11481	.	_	_

69-1	11482-11484	HC	_	_
69-2	11485-11488	had	_	_
69-3	11489-11493	2.4%	_	_
69-4	11494-11497	and	_	_
69-5	11498-11500	SZ	_	_
69-6	11501-11504	had	_	_
69-7	11505-11509	4.6%	_	_
69-8	11510-11512	of	_	_
69-9	11513-11516	all	_	_
69-10	11517-11523	epochs	_	_
69-11	11524-11532	rejected	_	_
69-12	11532-11533	.	_	_

70-1	11534-11537	The	_	_
70-2	11538-11543	total	_	_
70-3	11544-11550	number	_	_
70-4	11551-11553	of	_	_
70-5	11554-11560	epochs	_	_
70-6	11561-11565	used	_	_
70-7	11566-11569	for	_	_
70-8	11570-11577	further	_	_
70-9	11578-11586	analysis	_	_
70-10	11587-11595	included	_	_
70-11	11596-11599	401	_	_
70-12	11600-11602	EC	_	_
70-13	11602-11603	,	_	_
70-14	11604-11607	402	_	_
70-15	11608-11610	EO	_	_
70-16	11611-11617	epochs	_	_
70-17	11618-11620	in	_	_
70-18	11621-11623	HC	_	_
70-19	11623-11624	,	_	_
70-20	11625-11628	and	_	_
70-21	11629-11632	393	_	_
70-22	11633-11635	EC	_	_
70-23	11635-11636	,	_	_
70-24	11637-11640	403	_	_
70-25	11641-11643	EO	_	_
70-26	11644-11650	epochs	_	_
70-27	11651-11653	in	_	_
70-28	11654-11656	SZ	_	_
70-29	11656-11657	.	_	_

71-1	11658-11661	The	_	_
71-2	11662-11668	number	_	_
71-3	11669-11671	of	_	_
71-4	11672-11678	closed	_	_
71-5	11678-11679	/	_	_
71-6	11679-11683	open	_	_
71-7	11684-11690	epochs	_	_
71-8	11691-11694	did	_	_
71-9	11695-11698	not	_	_
71-10	11699-11705	differ	_	_
71-11	11706-11713	between	_	_
71-12	11714-11720	groups	_	_
71-13	11721-11722	(	_	_
71-14	11722-11725	all	_	_
71-15	11726-11727	p	_	_
71-16	11727-11728	’	_	_
71-17	11728-11729	s	_	_
71-18	11729-11730	>	_	_
71-19	11730-11734	0.25	_	_
71-20	11734-11735	)	_	_
71-21	11735-11736	.	_	_

72-1	11737-11740	MEG	_	_
72-2	11741-11749	Spectral	_	_
72-3	11750-11758	Analyses	_	_
72-4	11759-11762	For	_	_
72-5	11763-11769	sensor	_	_
72-6	11770-11778	analysis	_	_
72-7	11778-11779	,	_	_
72-8	11780-11782	we	_	_
72-9	11783-11790	applied	_	_
72-10	11791-11794	the	_	_
72-11	11795-11802	summary	_	_
72-12	11803-11811	spectral	_	_
72-13	11812-11820	measures	_	_
72-14	11821-11830	described	_	_
72-15	11831-11833	in	_	_
72-16	11834-11836	to	_	_
72-17	11837-11845	simplify	_	_
72-18	11846-11859	multi-channel	_	_
72-19	11860-11863	MEG	_	_
72-20	11864-11872	spectral	_	_
72-21	11873-11877	data	_	_
72-22	11877-11878	.	_	_

73-1	11879-11884	Using	_	_
73-2	11885-11889	only	_	_
73-3	11890-11896	planar	_	_
73-4	11897-11909	gradiometers	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
73-5	11909-11910	,	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
73-6	11911-11914	the	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
73-7	11915-11921	sensor	_	_
73-8	11922-11927	array	_	_
73-9	11928-11931	was	_	_
73-10	11932-11939	divided	_	_
73-11	11940-11944	into	_	_
73-12	11945-11949	left	_	_
73-13	11950-11953	and	_	_
73-14	11954-11959	right	_	_
73-15	11960-11970	equivalent	_	_
73-16	11971-11978	regions	_	_
73-17	11978-11979	,	_	_
73-18	11980-11983	see	_	_
73-19	11984-11990	Figure	_	_
73-20	11991-11992	2	_	_
73-21	11992-11993	.	_	_

74-1	11994-12002	Spectral	_	_
74-2	12003-12008	power	_	_
74-3	12009-12012	was	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
74-4	12013-12022	estimated	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
74-5	12023-12028	using	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
74-6	12029-12035	Matlab	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
74-7	12035-12036	’	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
74-8	12036-12037	s	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
74-9	12038-12041	FFT	_	_
74-10	12042-12050	function	_	_
74-11	12051-12055	with	_	_
74-12	12056-12057	a	_	_
74-13	12058-12064	window	_	_
74-14	12065-12069	size	_	_
74-15	12070-12072	of	_	_
74-16	12073-12077	2048	_	_
74-17	12078-12081	for	_	_
74-18	12082-12085	the	_	_
74-19	12086-12095	following	_	_
74-20	12096-12105	frequency	_	_
74-21	12106-12111	bands	_	_
74-22	12111-12112	:	_	_
74-23	12113-12118	Delta	_	_
74-24	12119-12120	(	_	_
74-25	12120-12121	1	_	_
74-26	12121-12122	–	_	_
74-27	12122-12123	4	_	_
74-28	12124-12126	Hz	_	_
74-29	12126-12127	)	_	_
74-30	12127-12128	,	_	_
74-31	12129-12134	Theta	_	_
74-32	12135-12136	(	_	_
74-33	12136-12137	5	_	_
74-34	12137-12138	–	_	_
74-35	12138-12139	8	_	_
74-36	12140-12142	Hz	_	_
74-37	12142-12143	)	_	_
74-38	12143-12144	,	_	_
74-39	12145-12150	Alpha	_	_
74-40	12151-12152	(	_	_
74-41	12152-12153	9	_	_
74-42	12153-12154	–	_	_
74-43	12154-12156	13	_	_
74-44	12157-12159	Hz	_	_
74-45	12159-12160	)	_	_
74-46	12160-12161	,	_	_
74-47	12162-12166	Beta	_	_
74-48	12167-12168	(	_	_
74-49	12168-12170	14	_	_
74-50	12170-12171	–	_	_
74-51	12171-12173	29	_	_
74-52	12174-12176	Hz	_	_
74-53	12176-12177	)	_	_
74-54	12177-12178	,	_	_
74-55	12179-12182	and	_	_
74-56	12183-12188	Gamma	_	_
74-57	12189-12190	(	_	_
74-58	12190-12192	31	_	_
74-59	12192-12193	–	_	_
74-60	12193-12195	58	_	_
74-61	12196-12198	Hz	_	_
74-62	12198-12199	)	_	_
74-63	12199-12200	.	_	_

75-1	12201-12209	Spectral	_	_
75-2	12210-12218	measures	_	_
75-3	12219-12227	included	_	_
75-4	12227-12228	:	_	_
75-5	12229-12234	power	_	_
75-6	12234-12235	,	_	_
75-7	12236-12246	normalized	_	_
75-8	12247-12252	power	_	_
75-9	12252-12253	,	_	_
75-10	12254-12264	half-power	_	_
75-11	12264-12265	,	_	_
75-12	12266-12273	Shannon	_	_
75-13	12274-12282	Spectral	_	_
75-14	12283-12290	Entropy	_	_
75-15	12291-12292	(	_	_
75-16	12292-12295	SSE	_	_
75-17	12295-12296	)	_	_
75-18	12296-12297	,	_	_
75-19	12298-12301	and	_	_
75-20	12302-12307	alpha	_	_
75-21	12308-12318	reactivity	_	_
75-22	12318-12319	.	_	_

76-1	12320-12330	Normalized	_	_
76-2	12331-12336	power	_	_
76-3	12337-12340	was	_	_
76-4	12341-12349	obtained	_	_
76-5	12350-12352	by	_	_
76-6	12353-12361	dividing	_	_
76-7	12362-12365	the	_	_
76-8	12366-12371	power	_	_
76-9	12372-12378	within	_	_
76-10	12379-12382	the	_	_
76-11	12383-12392	frequency	_	_
76-12	12393-12397	band	_	_
76-13	12398-12400	by	_	_
76-14	12401-12406	total	_	_
76-15	12407-12408	1	_	_
76-16	12408-12409	–	_	_
76-17	12409-12411	50	_	_
76-18	12412-12414	Hz	_	_
76-19	12415-12420	power	_	_
76-20	12420-12421	.	_	_

77-1	12422-12426	Half	_	_
77-2	12427-12432	power	_	_
77-3	12433-12436	was	_	_
77-4	12437-12444	defined	_	_
77-5	12445-12447	as	_	_
77-6	12448-12451	the	_	_
77-7	12452-12460	midpoint	_	_
77-8	12461-12470	frequency	_	_
77-9	12471-12476	where	_	_
77-10	12477-12481	half	_	_
77-11	12482-12484	of	_	_
77-12	12485-12488	the	_	_
77-13	12489-12494	power	_	_
77-14	12495-12497	is	_	_
77-15	12498-12503	below	_	_
77-16	12503-12504	/	_	_
77-17	12504-12509	above	_	_
77-18	12510-12513	for	_	_
77-19	12514-12517	the	_	_
77-20	12518-12519	1	_	_
77-21	12519-12520	–	_	_
77-22	12520-12522	50	_	_
77-23	12523-12525	Hz	_	_
77-24	12526-12531	range	_	_
77-25	12532-12535	and	_	_
77-26	12536-12545	indicates	_	_
77-27	12546-12553	overall	_	_
77-28	12554-12562	spectral	_	_
77-29	12563-12568	power	_	_
77-30	12569-12575	shifts	_	_
77-31	12576-12580	from	_	_
77-32	12581-12584	low	_	_
77-33	12585-12587	to	_	_
77-34	12588-12592	high	_	_
77-35	12593-12604	frequencies	_	_
77-36	12604-12605	.	_	_

78-1	12606-12611	Alpha	_	_
78-2	12612-12622	reactivity	_	_
78-3	12623-12626	was	_	_
78-4	12627-12637	calculated	_	_
78-5	12638-12643	using	_	_
78-6	12644-12654	normalized	_	_
78-7	12655-12663	spectral	_	_
78-8	12664-12669	power	_	_
78-9	12670-12676	values	_	_
78-10	12677-12681	with	_	_
78-11	12682-12685	the	_	_
78-12	12686-12695	following	_	_
78-13	12695-12696	:	_	_
78-14	12697-12698	(	_	_
78-15	12698-12703	EC-EO	_	_
78-16	12703-12704	)	_	_
78-17	12704-12705	/	_	_
78-18	12705-12707	EO	_	_
78-19	12707-12708	.	_	_

79-1	12709-12715	Global	_	_
79-2	12716-12724	measures	_	_
79-3	12725-12729	were	_	_
79-4	12730-12733	the	_	_
79-5	12734-12741	average	_	_
79-6	12742-12744	of	_	_
79-7	12745-12748	all	_	_
79-8	12749-12756	regions	_	_
79-9	12757-12760	and	_	_
79-10	12761-12773	gradiometers	_	_
79-11	12773-12774	.	_	_

80-1	12775-12778	For	_	_
80-2	12779-12785	source	_	_
80-3	12786-12794	analysis	_	_
80-4	12794-12795	,	_	_
80-5	12796-12799	the	_	_
80-6	12800-12808	cortical	_	_
80-7	12809-12816	surface	_	_
80-8	12817-12819	of	_	_
80-9	12820-12824	each	_	_
80-10	12825-12836	participant	_	_
80-11	12837-12840	was	_	_
80-12	12841-12854	reconstructed	_	_
80-13	12855-12859	from	_	_
80-14	12860-12862	T1	_	_
80-15	12862-12863	-	_	_
80-16	12863-12871	weighted	_	_
80-17	12872-12875	MRI	_	_
80-18	12876-12881	files	_	_
80-19	12882-12887	using	_	_
80-20	12888-12898	FreeSurfer	_	_
80-21	12899-12903	with	_	_
80-22	12904-12905	a	_	_
80-23	12906-12916	repeatedly	_	_
80-24	12917-12927	subdivided	_	_
80-25	12928-12938	octahedron	_	_
80-26	12939-12941	as	_	_
80-27	12942-12945	the	_	_
80-28	12946-12953	spatial	_	_
80-29	12954-12965	subsampling	_	_
80-30	12966-12972	method	_	_
80-31	12972-12973	,	_	_
80-32	12974-12982	creating	_	_
80-33	12983-12988	4,098	_	_
80-34	12989-12998	locations	_	_
80-35	12999-13002	per	_	_
80-36	13003-13013	hemisphere	_	_
80-37	13014-13018	with	_	_
80-38	13019-13020	a	_	_
80-39	13021-13027	source	_	_
80-40	13028-13033	space	_	_
80-41	13034-13036	of	_	_
80-42	13037-13040	4.9	_	_
80-43	13041-13043	mm	_	_
80-44	13043-13044	.	_	_

81-1	13045-13051	Source	_	_
81-2	13052-13060	analysis	_	_
81-3	13061-13064	was	_	_
81-4	13065-13074	performed	_	_
81-5	13075-13079	with	_	_
81-6	13080-13083	MNE	_	_
81-7	13084-13092	software	_	_
81-8	13093-13098	using	_	_
81-9	13099-13101	an	_	_
81-10	13102-13114	anatomically	_	_
81-11	13115-13126	constrained	_	_
81-12	13127-13133	linear	_	_
81-13	13134-13144	estimation	_	_
81-14	13145-13152	inverse	_	_
81-15	13153-13158	model	_	_
81-16	13159-13164	known	_	_
81-17	13165-13167	as	_	_
81-18	13168-13175	dynamic	_	_
81-19	13176-13187	statistical	_	_
81-20	13188-13198	parametric	_	_
81-21	13199-13206	mapping	_	_
81-22	13207-13208	(	_	_
81-23	13208-13212	dSPM	_	_
81-24	13212-13213	)	_	_
81-25	13213-13214	.	_	_

82-1	13215-13218	The	_	_
82-2	13219-13233	regularization	_	_
82-3	13234-13243	parameter	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
82-4	13244-13256	corresponded	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
82-5	13257-13261	with	_	_
82-6	13262-13263	a	_	_
82-7	13264-13279	signal-to-noise	_	_
82-8	13280-13285	ratio	_	_
82-9	13286-13288	of	_	_
82-10	13289-13290	3	_	_
82-11	13290-13291	.	_	_

83-1	13292-13298	Source	_	_
83-2	13299-13310	orientation	_	_
83-3	13311-13314	had	_	_
83-4	13315-13316	a	_	_
83-5	13317-13322	loose	_	_
83-6	13323-13333	constraint	_	_
83-7	13334-13336	of	_	_
83-8	13337-13340	0.2	_	_
83-9	13340-13341	.	_	_

84-1	13342-13345	The	_	_
84-2	13346-13353	forward	_	_
84-3	13354-13362	solution	_	_
84-4	13363-13366	was	_	_
84-5	13367-13377	calculated	_	_
84-6	13378-13382	with	_	_
84-7	13383-13384	a	_	_
84-8	13385-13391	single	_	_
84-9	13392-13397	layer	_	_
84-10	13398-13399	(	_	_
84-11	13399-13404	inner	_	_
84-12	13405-13410	skull	_	_
84-13	13410-13411	)	_	_
84-14	13412-13420	boundary	_	_
84-15	13421-13428	element	_	_
84-16	13429-13435	method	_	_
84-17	13435-13436	.	_	_

85-1	13437-13440	The	_	_
85-2	13441-13445	dSPM	_	_
85-3	13446-13453	inverse	_	_
85-4	13454-13459	model	_	_
85-5	13460-13470	identified	_	_
85-6	13471-13476	where	_	_
85-7	13477-13480	the	_	_
85-8	13481-13490	estimated	_	_
85-9	13491-13498	current	_	_
85-10	13499-13501	at	_	_
85-11	13502-13506	each	_	_
85-12	13507-13515	cortical	_	_
85-13	13516-13523	surface	_	_
85-14	13524-13530	vertex	_	_
85-15	13531-13539	differed	_	_
85-16	13540-13553	significantly	_	_
85-17	13554-13558	from	_	_
85-18	13559-13567	baseline	_	_
85-19	13568-13573	noise	_	_
85-20	13574-13575	(	_	_
85-21	13575-13580	empty	_	_
85-22	13581-13585	room	_	_
85-23	13586-13590	data	_	_
85-24	13590-13591	)	_	_
85-25	13591-13592	.	_	_

86-1	13593-13598	Power	_	_
86-2	13599-13607	spectral	_	_
86-3	13608-13615	density	_	_
86-4	13616-13617	(	_	_
86-5	13617-13620	PSD	_	_
86-6	13620-13621	)	_	_
86-7	13622-13630	measures	_	_
86-8	13631-13635	were	_	_
86-9	13636-13644	computed	_	_
86-10	13645-13649	from	_	_
86-11	13650-13656	epochs	_	_
86-12	13657-13662	using	_	_
86-13	13663-13664	a	_	_
86-14	13665-13676	multi-taper	_	_
86-15	13677-13683	method	_	_
86-16	13684-13688	with	_	_
86-17	13689-13697	Discrete	_	_
86-18	13698-13705	Prolate	_	_
86-19	13706-13716	Spheroidal	_	_
86-20	13717-13725	Sequence	_	_
86-21	13726-13727	(	_	_
86-22	13727-13731	DPSS	_	_
86-23	13731-13732	)	_	_
86-24	13733-13740	windows	_	_
86-25	13741-13744	for	_	_
86-26	13745-13749	each	_	_
86-27	13750-13759	frequency	_	_
86-28	13760-13764	band	_	_
86-29	13765-13768	and	_	_
86-30	13769-13775	region	_	_
86-31	13775-13776	,	_	_
86-32	13777-13782	using	_	_
86-33	13783-13784	7	_	_
86-34	13785-13791	tapers	_	_
86-35	13792-13794	at	_	_
86-36	13795-13796	4	_	_
86-37	13797-13799	Hz	_	_
86-38	13800-13803	and	_	_
86-39	13804-13811	regions	_	_
86-40	13812-13814	of	_	_
86-41	13815-13823	interest	_	_
86-42	13824-13829	based	_	_
86-43	13830-13832	on	_	_
86-44	13833-13836	the	_	_
86-45	13837-13847	FreeSurfer	_	_
86-46	13848-13851	DKT	_	_
86-47	13852-13857	atlas	_	_
86-48	13857-13858	.	_	_

87-1	13859-13862	PSD	_	_
87-2	13863-13873	represents	_	_
87-3	13874-13877	the	_	_
87-4	13878-13885	average	_	_
87-5	13886-13894	spectral	_	_
87-6	13895-13900	power	_	_
87-7	13901-13908	derived	_	_
87-8	13909-13913	from	_	_
87-9	13914-13918	each	_	_
87-10	13919-13924	voxel	_	_
87-11	13925-13929	time	_	_
87-12	13930-13936	series	_	_
87-13	13937-13940	for	_	_
87-14	13941-13945	each	_	_
87-15	13946-13954	regional	_	_
87-16	13955-13960	label	_	_
87-17	13960-13961	.	_	_

88-1	13962-13968	Global	_	_
88-2	13969-13977	measures	_	_
88-3	13978-13982	were	_	_
88-4	13983-13987	data	_	_
88-5	13988-13992	from	_	_
88-6	13993-13996	all	_	_
88-7	13997-14005	regional	_	_
88-8	14006-14012	labels	_	_
88-9	14013-14021	averaged	_	_
88-10	14021-14022	.	_	_

89-1	14023-14033	Normalized	_	_
89-2	14034-14039	power	_	_
89-3	14040-14043	was	_	_
89-4	14044-14052	obtained	_	_
89-5	14053-14055	by	_	_
89-6	14056-14064	dividing	_	_
89-7	14065-14068	the	_	_
89-8	14069-14074	power	_	_
89-9	14075-14081	within	_	_
89-10	14082-14091	frequency	_	_
89-11	14092-14096	band	_	_
89-12	14097-14099	by	_	_
89-13	14100-14103	the	_	_
89-14	14104-14109	total	_	_
89-15	14110-14111	1	_	_
89-16	14111-14112	–	_	_
89-17	14112-14114	58	_	_
89-18	14115-14117	Hz	_	_
89-19	14118-14123	power	_	_
89-20	14123-14124	.	_	_

90-1	14125-14135	Functional	_	_
90-2	14136-14143	network	_	_
90-3	14144-14156	connectivity	_	_
90-4	14157-14160	was	_	_
90-5	14161-14170	estimated	_	_
90-6	14171-14176	using	_	_
90-7	14177-14178	a	_	_
90-8	14179-14187	debiased	_	_
90-9	14188-14197	estimator	_	_
90-10	14198-14200	of	_	_
90-11	14201-14204	the	_	_
90-12	14205-14212	squared	_	_
90-13	14213-14221	weighted	_	_
90-14	14222-14227	phase	_	_
90-15	14228-14231	lag	_	_
90-16	14232-14237	index	_	_
90-17	14238-14239	(	_	_
90-18	14239-14252	wPLI-debiased	_	_
90-19	14252-14253	)	_	_
90-20	14253-14254	.	_	_

91-1	14255-14258	The	_	_
91-2	14259-14262	FNC	_	_
91-3	14263-14270	measure	_	_
91-4	14270-14271	,	_	_
91-5	14272-14285	wPLI-debiased	_	_
91-6	14285-14286	,	_	_
91-7	14287-14294	detects	_	_
91-8	14295-14299	true	_	_
91-9	14300-14307	changes	_	_
91-10	14308-14310	in	_	_
91-11	14311-14332	phase-synchronization	_	_
91-12	14332-14333	,	_	_
91-13	14334-14339	while	_	_
91-14	14340-14348	reducing	_	_
91-15	14349-14352	the	_	_
91-16	14353-14362	influence	_	_
91-17	14363-14365	of	_	_
91-18	14366-14372	common	_	_
91-19	14373-14378	noise	_	_
91-20	14379-14386	sources	_	_
91-21	14386-14387	,	_	_
91-22	14388-14395	changes	_	_
91-23	14396-14398	in	_	_
91-24	14399-14404	phase	_	_
91-25	14405-14407	of	_	_
91-26	14408-14417	coherency	_	_
91-27	14417-14418	,	_	_
91-28	14419-14422	and	_	_
91-29	14423-14429	avoids	_	_
91-30	14430-14440	spuriously	_	_
91-31	14441-14450	increases	_	_
91-32	14451-14453	by	_	_
91-33	14454-14471	volume-conduction	_	_
91-34	14471-14472	.	_	_

92-1	14473-14475	It	_	_
92-2	14476-14485	estimates	_	_
92-3	14486-14489	the	_	_
92-4	14490-14496	extent	_	_
92-5	14497-14499	of	_	_
92-6	14500-14508	observed	_	_
92-7	14509-14514	phase	_	_
92-8	14515-14520	leads	_	_
92-9	14521-14524	and	_	_
92-10	14525-14529	lags	_	_
92-11	14530-14532	by	_	_
92-12	14533-14536	the	_	_
92-13	14537-14546	magnitude	_	_
92-14	14547-14549	of	_	_
92-15	14550-14553	the	_	_
92-16	14554-14563	imaginary	_	_
92-17	14564-14573	component	_	_
92-18	14574-14576	of	_	_
92-19	14577-14580	the	_	_
92-20	14581-14595	cross-spectrum	_	_
92-21	14595-14596	.	_	_

93-1	14597-14600	All	_	_
93-2	14601-14605	data	_	_
93-3	14606-14610	were	_	_
93-4	14611-14619	exported	_	_
93-5	14620-14622	to	_	_
93-6	14623-14629	MATLAB	_	_
93-7	14630-14631	(	_	_
93-8	14631-14636	2018a	_	_
93-9	14636-14637	,	_	_
93-10	14638-14647	MathWorks	_	_
93-11	14647-14648	)	_	_
93-12	14649-14652	and	_	_
93-13	14653-14656	run	_	_
93-14	14657-14664	through	_	_
93-15	14665-14671	custom	_	_
93-16	14672-14679	scripts	_	_
93-17	14679-14680	.	_	_

94-1	14681-14691	Intraclass	_	_
94-2	14692-14703	Correlation	_	_
94-3	14704-14705	(	_	_
94-4	14705-14708	ICC	_	_
94-5	14708-14709	)	_	_
94-6	14710-14713	ICC	_	_
94-7	14714-14723	estimates	_	_
94-8	14724-14727	and	_	_
94-9	14728-14733	their	_	_
94-10	14734-14737	95%	_	_
94-11	14738-14748	confidence	_	_
94-12	14749-14758	intervals	_	_
94-13	14759-14763	were	_	_
94-14	14764-14774	calculated	_	_
94-15	14775-14777	in	_	_
94-16	14778-14782	SPSS	_	_
94-17	14783-14785	to	_	_
94-18	14786-14792	assess	_	_
94-19	14793-14796	the	_	_
94-20	14797-14804	between	_	_
94-21	14805-14808	and	_	_
94-22	14809-14823	within-subject	_	_
94-23	14824-14835	variability	_	_
94-24	14836-14841	using	_	_
94-25	14842-14843	a	_	_
94-26	14844-14851	two-way	_	_
94-27	14852-14857	mixed	_	_
94-28	14858-14865	effects	_	_
94-29	14866-14871	model	_	_
94-30	14872-14876	with	_	_
94-31	14877-14885	absolute	_	_
94-32	14886-14895	agreement	_	_
94-33	14895-14896	,	_	_
94-34	14897-14903	single	_	_
94-35	14904-14915	measurement	_	_
94-36	14916-14924	criteria	_	_
94-37	14924-14925	,	_	_
94-38	14926-14930	also	_	_
94-39	14931-14936	known	_	_
94-40	14937-14939	as	_	_
94-41	14940-14943	ICC	_	_
94-42	14944-14945	(	_	_
94-43	14945-14948	3,1	_	_
94-44	14948-14949	)	_	_
94-45	14950-14955	model	_	_
94-46	14955-14956	.	_	_

95-1	14957-14961	ICCs	_	_
95-2	14962-14966	were	_	_
95-3	14967-14977	calculated	_	_
95-4	14978-14981	for	_	_
95-5	14982-14990	multiple	_	_
95-6	14991-14995	rest	_	_
95-7	14996-15006	iterations	_	_
95-8	15006-15007	:	_	_
95-9	15008-15011	for	_	_
95-10	15012-15016	each	_	_
95-11	15017-15022	visit	_	_
95-12	15023-15024	(	_	_
95-13	15024-15030	across	_	_
95-14	15031-15034	one	_	_
95-15	15035-15039	hour	_	_
95-16	15039-15040	)	_	_
95-17	15040-15041	,	_	_
95-18	15042-15045	for	_	_
95-19	15046-15050	each	_	_
95-20	15051-15055	task	_	_
95-21	15056-15057	(	_	_
95-22	15057-15063	across	_	_
95-23	15064-15067	one	_	_
95-24	15068-15072	week	_	_
95-25	15072-15073	)	_	_
95-26	15074-15077	and	_	_
95-27	15078-15081	for	_	_
95-28	15082-15085	all	_	_
95-29	15086-15090	runs	_	_
95-30	15090-15091	.	_	_

96-1	15092-15096	ICCs	_	_
96-2	15097-15103	ranged	_	_
96-3	15104-15108	from	_	_
96-4	15109-15110	0	_	_
96-5	15111-15113	to	_	_
96-6	15114-15115	1	_	_
96-7	15116-15117	(	_	_
96-8	15117-15125	negative	_	_
96-9	15126-15132	values	_	_
96-10	15133-15139	scored	_	_
96-11	15140-15142	as	_	_
96-12	15143-15147	zero	_	_
96-13	15147-15148	)	_	_
96-14	15149-15153	with	_	_
96-15	15154-15160	higher	_	_
96-16	15161-15167	values	_	_
96-17	15168-15178	indicating	_	_
96-18	15179-15185	better	_	_
96-19	15186-15197	reliability	_	_
96-20	15197-15198	.	_	_

97-1	15199-15208	Following	_	_
97-2	15209-15212	the	_	_
97-3	15213-15223	guidelines	_	_
97-4	15224-15226	of	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
97-5	15227-15229	we	_	_
97-6	15230-15237	defined	_	_
97-7	15238-15242	ICCs	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
97-8	15243-15245	as	_	_
97-9	15245-15246	:	_	_
97-10	15247-15256	excellent	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
97-11	15257-15268	reliability	_	_
97-12	15269-15270	>	_	_
97-13	15270-15274	0.75	_	_
97-14	15274-15275	,	_	_
97-15	15276-15280	good	_	_
97-16	15281-15292	reliability	_	_
97-17	15293-15297	0.75	_	_
97-18	15297-15298	–	_	_
97-19	15298-15302	0.60	_	_
97-20	15302-15303	,	_	_
97-21	15304-15308	fair	_	_
97-22	15309-15320	reliability	_	_
97-23	15321-15325	0.59	_	_
97-24	15325-15326	–	_	_
97-25	15326-15330	0.40	_	_
97-26	15330-15331	,	_	_
97-27	15332-15335	and	_	_
97-28	15336-15340	poor	_	_
97-29	15341-15352	reliability	_	_
97-30	15353-15354	<	_	_
97-31	15354-15358	0.40	_	_
97-32	15358-15359	.	_	_

98-1	15360-15371	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
98-2	15372-15380	Analysis	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
98-3	15381-15384	All	_	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
98-4	15385-15395	statistics	_	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
98-5	15396-15400	were	_	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
98-6	15401-15410	performed	_	_
98-7	15411-15416	using	_	_
98-8	15417-15421	SPSS	_	_
98-9	15422-15423	(	_	_
98-10	15423-15430	version	_	_
98-11	15431-15433	25	_	_
98-12	15434-15437	for	_	_
98-13	15438-15447	Macintosh	_	_
98-14	15447-15448	)	_	_
98-15	15448-15449	.	_	_

99-1	15450-15455	Mixed	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
99-2	15456-15462	Effect	_	_
99-3	15463-15471	Repeated	_	_
99-4	15472-15489	Measures-Analysis	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
99-5	15490-15492	of	_	_
99-6	15493-15501	Variance	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
99-7	15502-15503	(	_	_
99-8	15503-15512	RM-ANOVAs	_	_
99-9	15512-15513	)	_	_
99-10	15514-15517	had	_	_
99-11	15518-15529	statistical	_	_
99-12	15530-15540	thresholds	_	_
99-13	15541-15544	set	_	_
99-14	15545-15547	at	_	_
99-15	15548-15549	p	_	_
99-16	15549-15550	<	_	_
99-17	15550-15554	0.05	_	_
99-18	15554-15555	.	_	_

100-1	15556-15574	Greenhouse-Geisser	_	_
100-2	15575-15586	corrections	_	_
100-3	15587-15591	were	_	_
100-4	15592-15596	made	_	_
100-5	15597-15600	for	_	_
100-6	15601-15611	sphericity	_	_
100-7	15612-15622	violations	_	_
100-8	15622-15623	.	_	_

101-1	15624-15627	The	_	_
101-2	15628-15643	between-subject	_	_
101-3	15644-15650	factor	_	_
101-4	15651-15654	was	_	_
101-5	15655-15660	Group	_	_
101-6	15661-15662	(	_	_
101-7	15662-15664	HC	_	_
101-8	15664-15665	,	_	_
101-9	15665-15667	SZ	_	_
101-10	15667-15668	)	_	_
101-11	15668-15669	,	_	_
101-12	15670-15684	within-subject	_	_
101-13	15685-15692	factors	_	_
101-14	15693-15701	included	_	_
101-15	15702-15712	Hemisphere	_	_
101-16	15713-15714	(	_	_
101-17	15714-15718	Left	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
101-18	15718-15719	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
101-19	15720-15725	Right	_	_
101-20	15725-15726	)	_	_
101-21	15726-15727	,	_	_
101-22	15728-15741	Resting-State	_	_
101-23	15742-15743	(	_	_
101-24	15743-15745	EO	_	_
101-25	15745-15746	,	_	_
101-26	15747-15749	EC	_	_
101-27	15749-15750	)	_	_
101-28	15750-15751	,	_	_
101-29	15752-15755	and	_	_
101-30	15755-15756	/	_	_
101-31	15756-15758	or	_	_
101-32	15759-15765	Region	_	_
101-33	15766-15767	[	_	_
101-34	15767-15775	Superior	_	_
101-35	15776-15784	Parietal	_	_
101-36	15785-15786	(	_	_
101-37	15786-15792	SupPar	_	_
101-38	15792-15793	)	_	_
101-39	15793-15794	,	_	_
101-40	15795-15803	Inferior	_	_
101-41	15804-15812	Parietal	_	_
101-42	15813-15814	(	_	_
101-43	15814-15820	InfPar	_	_
101-44	15820-15821	)	_	_
101-45	15821-15822	,	_	_
101-46	15823-15832	Precuneus	_	_
101-47	15832-15833	]	_	_
101-48	15834-15843	depending	_	_
101-49	15844-15846	on	_	_
101-50	15847-15854	measure	_	_
101-51	15855-15863	explored	_	_
101-52	15863-15864	.	_	_

102-1	15865-15876	Significant	_	_
102-2	15877-15889	interactions	_	_
102-3	15890-15894	were	_	_
102-4	15895-15906	followed-up	_	_
102-5	15907-15911	with	_	_
102-6	15912-15920	separate	_	_
102-7	15921-15928	one-way	_	_
102-8	15929-15935	ANOVAs	_	_
102-9	15935-15936	,	_	_
102-10	15937-15939	or	_	_
102-11	15940-15947	t-tests	_	_
102-12	15948-15950	on	_	_
102-13	15951-15954	the	_	_
102-14	15955-15962	factors	_	_
102-15	15963-15965	of	_	_
102-16	15966-15974	interest	_	_
102-17	15975-15979	with	_	_
102-18	15980-15990	familywise	_	_
102-19	15991-15999	multiple	_	_
102-20	16000-16011	comparisons	_	_
102-21	16012-16022	correction	_	_
102-22	16023-16028	using	_	_
102-23	16029-16034	false	_	_
102-24	16035-16044	discovery	_	_
102-25	16045-16049	rate	_	_
102-26	16050-16051	(	_	_
102-27	16051-16054	FDR	_	_
102-28	16054-16055	)	_	_
102-29	16056-16066	correction	_	_
102-30	16067-16071	with	_	_
102-31	16072-16073	q	_	_
102-32	16073-16074	=	_	_
102-33	16074-16078	0.05	_	_
102-34	16078-16079	.	_	_

